Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM230 + PD-1 Inhibitor in HER2-Related Advanced Solid Tumors
NCT07698587Phase 2Not yet recruiting
- Sponsor
- Biomissile Pharmaceuticals Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of BM230 in solid tumor, sponsored by Biomissile Pharmaceuticals Co., Ltd.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BM230
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07698587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698587.